In conclusion, we found that corilagin has the capability to ensure hepatic protection, to block NF-κB pathway, to provide anti-oxidative effects and to improve hepatic circulation in experimental intrahepatic cholestasis, which suggests that corilagin is a putative medication to treat cholestasis. Here, NFKB1 is linked to intrahepatic cholestasis.